SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • Barancik M, Bohacova V, Kvackajova J, Hudecova S, Krizanova O, Breier A. 2001. SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci 14: 2936.
  • Barnes CJ, Bagheri-Yarmand R, Mandal M, Yang Z, Clayman GL, Hong WK, Kumar R. 2003. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther 2: 345351.
  • Blackledge G, Averbuch S. 2004. Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer 90: 566572.
  • Burris HA, III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. 1997. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 24032413.
  • Chun PY, Feng FY, Scheurer AM, Davis MA, Lawrence TS, Nyati MK. 2006. Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res 66: 981988.
  • Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G. 2000. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6: 20532063.
  • Gaikwad A, Wolf JK, Brown J, Ramondetta LM, Smith JA. 2009. In vitro evaluation of the effects of gefitinib on the cytotoxic activity of selected anticancer agents in a panel of human endometrial cancer cell lines. J Oncol Pharm Pract 15: 3544.
  • Garcia R, Franklin RA, McCubrey JA. 2006. EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells. Cell Cycle 5: 28202826.
  • Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH. 2004. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1. J Clin Oncol 22: 777784.
  • Gounaris I, Zaki K, Corrie P. 2010. Options for the treatment of gemcitabine-resistant advanced pancreatic cancer. J Pancreas 11: 113123.
  • Guan J, Chen XP, Zhu H, Luo SF, Cao B, Ding L. 2004. Involvement of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance induced by HBx in hepatoma cell line. World J Gastroenterol 10: 35223527.
  • Heinemann V. 2002. Gemcitabine-based combination treatment of pancreatic cancer. Semin Oncol 29: 2535.
  • Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. 2004. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol 22: 785794.
  • Hoffmann K, Franz C, Xiao Z, Mohr E, Serba S, Buchler MW, Schemmer P. 2010. Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma. Anticancer Res 30: 45034508.
  • Jemal A, Siegel R, Xu J, Ward E. 2010. Cancer Statistics, 2010. CA Cancer J Clin 60; 277300.
  • Konig J, Hartel M, Nies AT, Martignoni ME, Guo J, Buchler MW, Friess H, Keppler D. 2005. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int J Cancer 115: 359367.
  • Kruh GD, Zeng H, Rea PA, Liu G, Chen ZS, Lee K, Belinsky MG. 2001. MRP subfamily transporters and resistance to anticancer agents. J Bioenerg Biomembr 33: 493501.
  • Li B, Chang CM, Yuan M, McKenna WG, Shu HK. 2003. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res 63: 74437450.
  • Li JS, Kleeff J, Giese N, Buchler MW, Korc M, Friess H. 2004. Gefitinib (‘Iressa’, ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. Int J Oncol 25: 203210.
  • Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402408.
  • Lu Z, Kleeff J, Shrikhande S, Zimmermann T, Korc M, Friess H, Buchler MW. 2000. Expression of the multidrug-resistance 1 (MDR1) gene and prognosis in human pancreatic cancer. Pancreas 21: 240247.
  • McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M. 2006. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46: 249279.
  • Merl MY, Li J, Saif MW. 2010. The first-line treatment for advanced pancreatic cancer. Highlights from the “2010 ASCO Gastrointestinal Cancers Symposium”. Orlando, FL, USA. January 22–24, 2010. J Pancreas 11: 148150.
  • O'Driscoll L, Walsh N, Larkin A, Ballot J, Ooi WS, Gullo G, O'Connor R, Clynes M, Crown J, Kennedy S. 2007. MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma. Anticancer Res 27: 21152120.
  • Pao W, Miller VA, Kris MG. 2004. ‘Targeting’ the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Semin Cancer Biol 14: 3340.
  • Qin B, Ariyama H, Baba E, Tanaka R, Kusaba H, Harada M, Nakano S. 2006. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. Cancer Chemother Pharmacol 58: 577584.
  • Rivera F, Lopez-Tarruella S, Vega-Villegas ME, Salcedo M. 2009. Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev 35: 335339.
  • Sagol O, Yavuzsen T, Oztop I, Ulukus C, Ylmaz U, Alakavuklar M, Karademir S, Obuz F, Astarcoglu H, Astarcoglu I. 2005. The effect of apoptotic activity, survivin, Ki-67, and P-glycoprotein expression on prognosis in pancreatic carcinoma. Pancreas 30: 343348.
  • Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. 2000. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6: 48854892.
  • Wang X, Martindale JL, Holbrook NJ. 2000. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 275: 3943539443.
  • Wu Z, Gioeli D, Conaway M, Weber MJ, Theodorescu D. 2008. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors. Prostate 68: 935944.
  • Yang CH, Huang CJ, Yang CS, Chu YC, Cheng AL, Whang-Peng J, Yang PC. 2005. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res 65: 69436949.
  • Yang JM, Vassil AD, Hait WN. 2001. Activation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf-MAPK pathway. Mol Pharmacol 60: 674680.
  • Zhao YP, Chen G, Feng B, Zhang TP, Ma EL, Wu YD. 2007. Microarray analysis of gene expression profile of multidrug resistance in pancreatic cancer. Chin Med J (Engl) 120: 17431752.
  • Zhao YP, Zhang LY, Liao Q, Guo JC, Chen G, Li JY. 2004. Detection of multidrug resistant gene 1 in pancreatic cancer. Hepatobiliary Pancreat Dis Int 3: 307310.
  • Zhou X, Zheng M, Chen F, Zhu Y, Yong W, Lin H, Sun Y, Han X. 2009. Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest. Anat Rec (Hoboken) 292: 11221127.